The promising novel strategy of HER2 abnormal breast cancers’ clinical treatment assumes alternate combinatory agents, including cyclin-dependent kinase (CDK) 4/6 inhibitors, endocrine therapy, cholesterol pathway inhibitors, or receptor tyrosine kinase (RTK) inhibitors [49]. This evidence concerns the gene ERBB2 and breast carcinoma.